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region for European countries and gender, age, race, and
region for the United States. Participants report if they
have been diagnosed with 5 mental and 12 physical health
conditions. Mental and physical health status is deﬁned
by the SF-8. Non-adherent attitudes are deﬁned by using
three attitudinal statements: use of another’s prescription,
frequent switching, and frequent missed doses. Respon-
dents report their degree of agreement on a ﬁve-point
scale. RESULTS: Overall, France has the highest per-
centage of people with non-adherent attitudes (18% use
another’s prescription; 3% frequently switch; 13% fre-
quently miss doses), and Great Britain has the lowest (8%
use another’s prescription; 2% frequently switch; 9% fre-
quently miss doses). People in all countries with non-
adherent attitudes are more likely to be younger and
less-educated. In Germany and Great Britain, those with
non-adherent attitudes are more likely to be male, and in
France and the US are more likely to be female. For all
countries, mental health is worse among those with non-
adherent attitudes. Physical health is worse among those
with non-adherent attitudes in Great Britain and the US,
but is the same or better in Germany and France. Respon-
dents with a mental health condition in Great Britain and
the United States are more likely to have non-adherent
attitudes. Results varied for France and Germany by 
speciﬁc mental health condition. CONCLUSION: Non-
adherent attitudes vary across countries. These differ-
ences should be considered in creating programs that
promote adherence.
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OBJECTIVES: Osteoporosis therapy places extensive
behavioral demands on patients, including the need for
precisely scheduled daily or weekly medication intake,
regular physical exercise and frequent visits to health care
providers. Although effective treatments are available,
compliance with osteoporosis therapy is known to be low.
It has previously been demonstrated that medication non-
compliance in actual practice—deﬁned as taking less than
80% of prescribed medications—signiﬁcantly increases
the risk of fractures. The objective of this study was 
to explore the effect of varying the deﬁnition of non-
compliance to identify the minimum level of compliance
required to reduce fracture risk. METHODS: Demo-
graphic, prescription drug use, physician services and
hospitalization information for women with osteoporosis
who were dispensed an osteoporosis medication between
1996 and 2001 was obtained from the Saskatchewan
Health data ﬁles. Fractures were identiﬁed by hospital-
ization or physician visits with a relevant diagnostic or
procedure code. Different levels of compliance were
deﬁned based on the proportion of time during which
patients had drugs available: <50% (poor), 50–80%
(medium), 80–90% (good), and >90% (excellent). A Cox
proportional hazards model was used to assess the effect
of compliance, deﬁned as a time-dependent covariate,
controlling for other known risk factors for fractures.
Patients were studied for up to three years following the
index prescription. RESULTS: Among 11,249 women
suffering from osteoporosis the overall fracture rate was
4.8 fractures per 100 person-years. Poor compliance led
to a 40% increase in fracture risk (95% CI: 19%–66%)
compared to excellent compliance, while medium com-
pliance increased risk by 20% (95% CI: 0%–43%). No
statistically signiﬁcant differences in fracture risk were
observed, however, between good and excellent com-
pliance. CONCLUSION: A high level of compliance
(80%–100%) is required to reduce osteoporosis-related
fracture risk.
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OBJECTIVES: 1) To determine if reﬁll-based measures 
of non-adherence could be constructed using claims data;
2) compare and contrast three different compliance 
measures; and 3) determine the degree to which each 
measure predicted hospitalization or emergency room 
events among Medicaid patients with schizophrenia.
METHODS: Retrospective case control study using Med-
icaid claims data. Subjects were 1426 patients with a
diagnosis of schizophrenia who had received at least one
Rx for an antipsychotic medication. Cases were patients
with an event; controls were randomly selected during the
same calendar quarter. Both were continuously eligible
and receiving ambulatory care for at least six months
before the index date. Demographic, medical care use,
comorbidity, and antipsychotic drug usage data were col-
lected. A “days out of therapy” measure, and 2 medica-
tion possession ratio (MPR) scores were computed from
dispensed prescription (Rx) records during the 120-day
window prior to the index event date. RESULTS: Days’
supply was missing or inaccurate for 5.2% of all Rx; and
12.5% of patients had at least one Rx with a missing
days’ supply. Days’ supply could be imputed for most
missing records using a simple algorithm. Two of the 3
compliance measures correlated with each other at r = .33
or higher. The two MPR measures demonstrated low sen-
sitivity for an event (<32%) but relatively high speciﬁcity
(>70%) regardless of cutoff level. The days out measure
demonstrated high sensitivity and low speciﬁcity. An
exploratory model predicting events was developed using
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multiple logit regression. The most important factors
were found to be depression or other mental health
comorbidity and previous hospitalization. Compliance
measures were not found to be important predictors.
CONCLUSIONS: It is feasible to compute compliance
measures based on Medicaid prescription claims records,
but other factors were found to be more important risk
factors for an event.
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OBJECTIVE: The SF-36 is a widely used generic measure
of health status. Whilst SF-36 provides a rich source 
of descriptive data, it shares a major disadvantage with
similar proﬁle measures that do not support the compu-
tation of an aggregate summary index. Proﬁle measures
of this type may demonstrate changes in overall health
status, but are inherently incapable of measuring the mag-
nitude of such change. This defect has been recognised
for some time and several remedial methods have been
proposed. These include separate algorithms published by
Fryback, Shmueli and Brazier. This paper reviews these
algorithms and considers the implications of their use 
in economic evaluation. METHODS: Journal articles
describing these three transformation models were used
as the basis of a forensic examination of the empirical evi-
dence offered in their support. The Brazier methodology,
based on a more fundamental remodeling of the SF-36,
was subjected to an extensive review that took account
of the derivation of an abbreviated descriptive system
referred to as the SF-6D. The implications of applying any
of these algorithms to the estimation of QALY gains was
tested using published results from a study that ﬁelded
the SF-36 alongside an asthma-speciﬁc measure.
RESULTS: Signiﬁcant defects in all three transforma-
tion models were identiﬁed; these included the failure of
regression models used to estimate index values and 
the imposition of researcher value judgment. The docu-
mented failure of the SF-6D models was conspicuous in
its original published account. Cost/QALY estimates
varied according to transformation model with the SF-6D
ratios being systematically lower than the others. CON-
CLUSIONS: There is demonstrable evidence that the 
SF-36 continues to be resistant to conversion into a 
single, summary index incorporating social preference
values. Continued misapplication of such transformation
methods is liable to degrade the status of cost-utility
analysis based on more robust methods of measuring
health outcomes.
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OBJECTIVES: Generic health status indexes convention-
ally require that full health and dead are valued as 1 and
0 respectively. When social preference weights for health
states are obtained using a visual analogue scaling (VAS)
technique their raw scores often lie on a scale with dif-
ferent endpoints (such as “best” and “worst” health). The
transformation of such “raw” scores to a 0–1 scale leads
to the exclusion of respondents who fail, for whatever
reason, to record a value for dead or full health. This
study reports on an alternative approach that does not
impose such strict inclusion criteria. METHODS: Data
from a postal valuation survey (n = 686) conducted in
Belgium are used to compare 2 different approaches: (a)
values for EQ-5D health states are transformed on a
within-respondent basis and median values then com-
puted; (b) median values for EQ-5D health states are
computed from the observed data and then transformed
to a 0–1 scale. Rankings, health state values and value
differences between pairs of states resulting from both
methods are compared. RESULTS: The exclusion rate
approaches 29% in the conventional approach and 5%
in the alternative approach. Transformed median valua-
tions are not signiﬁcantly different from median trans-
formed valuations. Correlation is 0.994 (p < 0.0005).
Health state rankings are identical in both approaches.
Although the value differences between pairs of states
differ between both methods, their correlation is very
high (0.998). CONCLUSIONS: Using median original
valuations in the analysis of EQ-5D valuation data are
theoretically appealing. It builds on the “median voter”
model and has the advantage of a lower respondent exclu-
sion rate. Given the need for transparency and the 
inclusive nature of the mode of analysis, aggregation of
observed VAS scores with subsequent transformation is
considered an acceptable alternative to the conventional
method with its associated data loss.
UT3
ESTIMATING HEALTH UTILITY FROM A
PHYSICAL FUNCTION ASSESSMENT IN
RHEUMATOID ARTHRITIS (RA) PATIENTS
TREATED WITH ADALIMUMAB (D2E7)
Boggs R, Sengupta N,Ashraf T
Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: Policymakers need cost utility estimates
when evaluating new biologic therapies in RA. Most clin-
ical trials of these therapies measure physical function,
then estimate utility from physical function. Adalimumab
(D2E7, Abbott) trials measured both physical function
